MCCP
RPTX

Mission Creek Capital Partners’s Repare Therapeutics RPTX Stock Holding History

Mission Creek Capital Partners’s Portfolio RPTX Stock Details RPTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-16,387
Closed -$503K – 242
2021
Q1 		$503K Buy
+16,387
New +$557K 0.08% 160

Other funds holding RPTX

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
CA
CHI Advisors New York $252M AUM 56.99% 1-Year Est. Return
MAM
MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

Mission Creek Capital Partners's RPTX Position: Q2 2021 in Review

Mission Creek Capital Partners sold out of Repare Therapeutics (RPTX) in Q2 2021, closing a stake of 16,387 shares — an estimated $503K sold.

Mission Creek Capital Partners first reported a position in RPTX in Q1 2021 and held it in 1 quarter. The position peaked at $503K in Q1 2021. 61 funds tracked by Wall St. Rank hold RPTX as of Q2 2021.

  • Mission Creek Capital Partners reported no remaining Repare Therapeutics position as of Q2 2021 after selling out during the quarter.
  • Mission Creek Capital Partners sold 16,387 Repare Therapeutics shares in Q2 2021, an estimated $503K.
  • Mission Creek Capital Partners first reported a position in Repare Therapeutics in Q1 2021 and held it in 1 quarter.
  • Mission Creek Capital Partners's Repare Therapeutics position peaked at $503K in Q1 2021.
  • 61 funds tracked by Wall St. Rank held Repare Therapeutics as of Q2 2021.

Based on Mission Creek Capital Partners's 13F filing for Q2 2021, filed 13 Aug 2021.